Lexon UK Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Lexon UK Limited Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lexon UK Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

Lexon UK Limited

Pharmaceutical Importer · United Kingdom · Diuretics Focus · $1.4M Total Trade · DGFT Verified

Lexon UK Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $1.4M across 2 products in 2 therapeutic categories. Based on 29 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Lexon UK Limited sources from 3 verified Indian suppliers, with Piramal Pharma Limited accounting for 58.3% of imports.

Lexon UK Limited — Import Portfolio & Supplier Network

Lexon UK Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Lexon UK Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Piramal Pharma Limited	$997.5K	26	58.3%
Sharon Bio Medicine Limited	$563.9K	15	32.9%
Natco Pharma Limited	$150.0K

What Formulations Does Lexon UK Limited Import?

Formulation	Value	Ships
Spironolactone 100MG tabs pvc bl 2x14s	$100.0K	2
Spironolactone 50MG tabs pvc bl 2x14s	$100.0K	2
Spironolactone 12.5MG TAB vc bl2x14s uk(400691057) (95,466.000 sb )	$64.0K	3
Spironolactone 12.5MG TAB pvc bl2x14s uk(400691057) (71,629.000 sb )	$53.0K	3
Spironolactone 25MG tabs pvc bl 2 x 14s	$50.0K	1
Spironolactone 12.5MG tabs pvc bl 2x14s	$50.0K	1
Spironolactone 12 5MG tabs pvc bl 2x14s 400691038 89987 00	$50.0K	1
Spironolactone 25MG tabs pvc bl 2x14s	$50.0K	1
Spironolactone 50MG tabs pvc bl 2x14s 400691044 95726.000	$50.0K	1
Spironolactone 25MG tabs pvc bl 2x14s 400691041 101277.000	$50.0K	1
Spironolactone 25MG tabs pvc bl 2x14s (400691041) (103,536.000 sb )	$50.0K	1
Spironolactone 50MG tabs pvc bl 2x14s (400691044) (72,089.000 sb)	$50.0K	1
Anastrozole 1MG tablets 28's (qty.107855x28's=3019940 nos)(rodtep entry no.10112)(our ref ci no.124053)	$50.0K	1
(400691044) spironolactone 50MG tabs pvcbl 2x14s (46,646.000 sb)	$50.0K	1
Anastrozole 1MG tablets 28's (qty.166570x28's=4663960 nos)(rodtep entry no.10112)(our ref ci no.125006)	$50.0K	1

Lexon UK Limited imports 38 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Spironolactone	Diuretics	$1.3M	26	0.7%	14
2	Anastrozole	Advanced Oncology	$150.0K	3	0.1%	14

Lexon UK Limited imports 2 pharmaceutical products across 2 categories into United Kingdom totaling $1.4M.

Lexon UK Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Lexon UK Limited, established in 1995, is a prominent pharmaceutical wholesaler headquartered in Redditch, England. The company specializes in the distribution of pharmaceutical products, including both prescription and over-the-counter medications, as well as veterinary medicines. With a workforce of approximately 683 employees, Lexon UK Limited serves a diverse clientele, including retail pharmacies, hospitals, and healthcare providers across the United Kingdom.

In April 2023, Lexon UK Limited was acquired by Well Pharmacy, a subsidiary of the Bestway Group. This acquisition aimed to enhance Well Pharmacy's presence in the pharmaceutical wholesale sector and expand its distribution capabilities. The integration of Lexon UK Limited into Well Pharmacy's operations is expected to strengthen the supply chain and improve service delivery to healthcare providers and patients nationwide. (easterneye.biz)

2Distribution Network

Lexon UK Limited operates a comprehensive distribution network with multiple depots strategically located across the United Kingdom and Ireland. These facilities are situated in Redditch, Leeds, Durham, East Kilbride, and Dublin, enabling the company to effectively serve a wide range of customers. The distribution centers are equipped with advanced logistics capabilities, including temperature-controlled storage and efficient order fulfillment systems, ensuring timely and secure delivery of pharmaceutical products. (easterneye.biz)

The geographic coverage of Lexon UK Limited's distribution network spans the Midlands, northwest, and northeast of England, as well as parts of Ireland. This extensive reach allows the company to cater to the needs of approximately 3,000 retail pharmacy customers and numerous community pharmacies, facilitating access to essential medications across these regions. (easterneye.biz)

3Industry Role

As a pharmaceutical wholesaler, Lexon UK Limited plays a pivotal role in the United Kingdom's pharmaceutical supply chain. The company sources a diverse range of pharmaceutical products from various manufacturers, including generic and over-the-counter medications, and distributes them to retail pharmacies, hospitals, and other healthcare providers. This intermediary function ensures that essential medicines are readily available to meet the demands of the healthcare sector.

In addition to its wholesale operations, Lexon UK Limited has expanded its services to include the operation of community pharmacies under the trading name Knights Pharmacy. This vertical integration allows the company to directly serve patients, providing a comprehensive approach to pharmaceutical distribution and retail. (easterneye.biz)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Lexon UK Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Lexon UK Limited's sourcing strategy exhibits a notable concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $1.4 million USD from India, encompassing 29 shipments and 38 unique formulations. The top two products imported were Spironolactone ($1.3 million, 26 shipments) and Anastrozole ($150,000, 3 shipments). These imports were sourced from three Indian suppliers: Piramal Pharma Limited, Sharon Bio Medicine Limited, and Natco Pharma Limited.

The high concentration of imports from a limited number of suppliers indicates a strategic sourcing approach, potentially leveraging established relationships and favorable terms. However, this dependency also introduces risks related to supply chain disruptions, such as production delays or regulatory changes in the supplier's country. The stability of these supplier relationships is crucial for maintaining a consistent supply of essential pharmaceutical products.

2Supply Chain Resilience

The resilience of Lexon UK Limited's supply chain, particularly concerning its Indian suppliers, is a critical factor in ensuring uninterrupted access to pharmaceutical products. The company's reliance on three primary suppliers for a substantial portion of its imports suggests a streamlined procurement process but also highlights potential vulnerabilities.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the safety, quality, and efficacy of medicines and medical devices. The MHRA is responsible for granting marketing authorizations, conducting inspections, and ensuring compliance with Good Manufacturing Practice (GMP) standards.

The regulatory framework governing pharmaceutical imports into the UK is primarily outlined in the Human Medicines Regulations 2012. These regulations stipulate the requirements for importing, manufacturing, and distributing medicinal products, including the necessity for importers to hold a Wholesale Dealer’s License (WDA) and comply with GMP standards.

2Import Licensing & GMP

Importers of pharmaceutical products into the United Kingdom must obtain a Wholesale Dealer’s License (WDA) from the MHRA. This license authorizes the holder to import, store, and distribute medicinal products within the UK. Additionally, imported medicines must comply with GMP standards, ensuring that they are manufactured and tested in accordance with internationally recognized quality standards.

The MHRA recognizes GMP certificates from various regulatory bodies, including the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the importation of medicines from countries with established GMP standards, such as India.

Lexon UK Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Lexon UK Limited's focus on importing finished pharmaceutical formulations, particularly in the therapeutic categories of diuretics and advanced oncology, aligns with market demands for essential and specialized medications. The substantial import value of Spironolactone and Anastrozole indicates a strategic emphasis on these high-demand products. This product strategy is driven by the need to provide healthcare providers with reliable access to critical treatments for conditions such as hypertension, heart failure, and various cancers.

The company's sourcing of these products from India reflects a strategic decision to leverage cost-effective manufacturing while maintaining product quality. India's established pharmaceutical industry, with its adherence to international GMP standards, offers a reliable supply of high-quality generic medications.

2Sourcing Profile

Lexon UK Limited's sourcing strategy is centered on importing generic drug formulations, primarily from India. This approach allows the company to offer cost-effective alternatives to branded medications, making essential treatments more accessible to patients. The focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market products that can be directly distributed to healthcare providers.

India's role as a key supplier in Lexon UK Limited's procurement strategy underscores the importance of maintaining strong relationships with Indian pharmaceutical manufacturers. Ensuring compliance with international quality standards and regulatory requirements is crucial for sustaining this sourcing model.

Frequently Asked Questions — Lexon UK Limited

What products does Lexon UK Limited import from India?

Lexon UK Limited imports 2 pharmaceutical products across 2 categories. Top imports: Spironolactone ($1.3M), Anastrozole ($150.0K).

Who supplies pharmaceuticals to Lexon UK Limited from India?

Lexon UK Limited sources from 3 verified Indian suppliers. The primary supplier is Piramal Pharma Limited (58.3% of imports, $997.5K).

What is Lexon UK Limited's total pharmaceutical import value?

Lexon UK Limited's total pharmaceutical import value from India is $1.4M, based on 29 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Lexon UK Limited focus on?

Lexon UK Limited imports across 2 categories. The largest: Diuretics (89.7%), Advanced Oncology (10.3%).

Get Full Lexon UK Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.